Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Executive Summary

• Profound Medical announced that The Hong Center Scottsdale has independently performed 200 TULSA‑PRO® procedures, a world‑first milestone demonstrating a urologist‑only workflow without radiologist involvement.
• The achievement highlights the scalability and ease of use of the AI‑powered, MRI‑guided TULSA Procedure for prostate therapy, potentially expanding market adoption.
• CEO Arun Menawat emphasized the clinical impact—hundreds of men treated with cancer‑free outcomes and preserved quality of life—underscoring the technology’s role as a next‑generation alternative to surgery or radiation.

Key Details

• Milestone: 200 TULSA Procedures™ performed independently by Dr. Y. Mark Hong, urologist at The Hong Center Scottsdale (Phoenix, AZ).
• Significance: First instance where a urologist completed the full workflow—from MRI image planning to ultrasound ablation—without radiologist assistance.
• Clinical Impact: Demonstrates that TULSA‑PRO® can be delivered safely by a single specialist, maintaining high cure rates, minimal blood loss, no hospitalization, and preservation of urinary/sexual function.
• Procedure Scope: Includes whole‑gland, focal, BPH, and salvage cases; treats complex prostate cancers with rapid recovery.
• Technology Highlights: AI‑enhanced planning, real‑time MRI thermography, autonomous temperature control, robotically driven transurethral ultrasound; CE marked, Health Canada approved, FDA 510(k) cleared.
• CEO Quote (Arun Menawat): Emphasized the milestone’s importance for patient outcomes and the broader adoption of incision‑free prostate therapy.
• Physician Quote (Dr. Hong): Stated that the independent workflow positions TULSA as a future first‑line treatment, potentially replacing radical prostatectomy.

Notable Quotes

“This 200‑procedure milestone is more than a number – it represents the hundreds of men who are now living cancer‑free, with preserved quality of life, thanks to his expertise and dedication.” – Arun Menawat, CEO & Chairman, Profound Medical Corp.

“In my view, TULSA represents the future of prostate disease treatment, one that will ultimately replace radical prostatectomy as a first‑line option for prostate cancer.” – Dr. Y. Mark Hong, Founder, The Hong Center Scottsdale.